Effects of Astragalus Polysaccharide on Mechanical Characterization of Liver Sinusoidal Endothelial Cells by Atomic Force Microscopy at Nanoscale

Li, Wenliang; Li, Juan-Mei; Jiao, Yang; Xu, Chunming; Zhang, Shasha; Yan, Jie; Zhang, Tingting; Zhao, Huihui

doi:10.1007/s11655-017-2964-0

Cited by 4 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When studying the effects of Astragalus polysaccharide (APS), which is the primary effective component of the Chinese herbal medicine Astragalus membranaceus , on nanoscale mechanical properties of LSECs in rats, we found that as APS concentration increased, the value of Young’s modulus presented an increasing trend, and the surface topography demonstrated that APS was capable of increasing the total area of fenestrae. The observed changes in mechanical properties of LSECs may provide a new therapeutic strategy for mechanistic research of anti-hepatic fibrosis treatments in Chinese medicine[ 52 ].…”

Section: Lsecs In Liver Fibrosismentioning

confidence: 99%

Pathological process of liver sinusoidal endothelial cells in liver diseases

Liu

et al. 2017

WJG

Self Cite

View full text Add to dashboard Cite

Cirrhosis develops from liver fibrosis and is the severe pathological stage of all chronic liver injury. Cirrhosis caused by hepatitis B virus and hepatitis C virus infection is especially common. Liver fibrosis and cirrhosis involve excess production of extracellular matrix, which is closely related to liver sinusoidal endothelial cells (LSECs). Damaged LSECs can synthesize transforming growth factor-beta and platelet-derived growth factor, which activate hepatic stellate cells and facilitate the synthesis of extracellular matrix. Herein, we highlight the angiogenic cytokines of LSECs related to liver fibrosis and cirrhosis at different stages and focus on the formation and development of liver fibrosis and cirrhosis. Inhibition of LSEC angiogenesis and antiangiogenic therapy are described in detail. Targeting LSECs has high therapeutic potential for liver diseases. Further understanding of the mechanism of action will provide stronger evidence for the development of anti-LSEC drugs and new directions for diagnosis and treatment of liver diseases.

show abstract

Section: Lsecs In Liver Fibrosismentioning

confidence: 99%

Pathological process of liver sinusoidal endothelial cells in liver diseases

Liu

et al. 2017

WJG

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition, bile stasis causes cholestatic liver fibrosis ( Hasegawa et al, 2021 ), intraperitoneal administration of Astragaloside in a bile duct ligation model of hepatic fibrosis in rats attenuated the development of fibrosis as assessed by collagen deposition, myofibroblast activation, and hepatobiliary function ( Yongping et al, 2015 ). Furthermore, fibrosis leads to changes in cellular structure and mechanical properties ( Natarajan et al, 2017 ), Astragalus polysaccharide can increase the stiffness of liver sinusoidal endothelial cells, which may provide a new mechanism for Chinese medicine to fight hepatic fibrosis ( Lu et al, 2018 ). Calycosin can reduce α-SMA in both carbon tetrachloride-induced hepatic fibrosis mice and non-alcoholic steatohepatitis mice, collagen I decrease is also observed in the carbon tetrachloride model, this is related to multiple mechanisms, including inhibiting oxidative stress, matrix metalloproteinase-1/tissue inhibitor of metalloproteinase-1 (MMP-1/TIMP-1) system and activating janus kinase 2- signal transducer and activator of transcription 3 (JAK2-STAT3) pathway, while Calycosin activates farnesoid X receptor (FXR) to attenuate hepatic fibrosis in non-alcoholic steatohepatitis mice ( Duan et al, 2017 ; Zhang et al, 2021a ).…”

Section: Effect Of Astragalus On Fibrotic Diseasesmentioning

confidence: 99%

Astragalus and its formulas as a therapeutic option for fibrotic diseases: Pharmacology and mechanisms

Zhu¹,

Chai

Xiao

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Fibrosis is the abnormal deposition of extracellular matrix, characterized by accumulation of collagen and other extracellular matrix components, which causes organ dysfunction and even death. Despite advances in understanding fibrosis pathology and clinical management, there is no treatment for fibrosis that can prevent or reverse it, existing treatment options may lead to diarrhea, nausea, bleeding, anorexia, and liver toxicity. Thus, effective drugs are needed for fibrotic diseases. Traditional Chinese medicine has played a vital role in fibrotic diseases, accumulating evidence has demonstrated that Astragalus (Astragalus mongholicus Bunge) can attenuate multiple fibrotic diseases, which include liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, renal fibrosis, cardiac fibrosis, and so on, mechanisms may be related to inhibition of epithelial-mesenchymal transition (EMT), reactive oxygen species (ROS), transforming growth factor beta 1 (TGF-β1)/Smads, apoptosis, inflammation pathways. The purpose of this review was to summarize the pharmacology and mechanisms of Astragalus in treating fibrotic diseases, the data reviewed demonstrates that Astragalus is a promising anti-fibrotic drug, its main anti-fibrotic components are Calycosin, Astragaloside IV, Astragalus polysaccharides and formononetin. We also review formulas that contain Astragalus with anti-fibrotic effects, in which Astragalus and Salvia miltiorrhiza Bunge, Astragalus and Angelica sinensis (Oliv.) Diels are the most commonly used combinations. We propose that combining active components into new formulations may be a promising way to develop new drugs for fibrosis. Besides, we expect Astragalus to be accepted as a clinically effective method of treating fibrosis.

show abstract

Research Progress in Astragalus Membranaceus and Its Active Components on Immune Responses in Liver Fibrosis

Liu

2019

Chin. J. Integr. Med.

View full text Add to dashboard Cite

Effects of Astragalus Polysaccharide on Mechanical Characterization of Liver Sinusoidal Endothelial Cells by Atomic Force Microscopy at Nanoscale

Cited by 4 publications

References 13 publications

Pathological process of liver sinusoidal endothelial cells in liver diseases

Pathological process of liver sinusoidal endothelial cells in liver diseases

Astragalus and its formulas as a therapeutic option for fibrotic diseases: Pharmacology and mechanisms

Research Progress in Astragalus Membranaceus and Its Active Components on Immune Responses in Liver Fibrosis

Contact Info

Product

Resources

About